JP2023503868A5 - - Google Patents

Info

Publication number
JP2023503868A5
JP2023503868A5 JP2022528714A JP2022528714A JP2023503868A5 JP 2023503868 A5 JP2023503868 A5 JP 2023503868A5 JP 2022528714 A JP2022528714 A JP 2022528714A JP 2022528714 A JP2022528714 A JP 2022528714A JP 2023503868 A5 JP2023503868 A5 JP 2023503868A5
Authority
JP
Japan
Prior art keywords
fusion protein
structural unit
complex according
receptor
protein complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022528714A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023503868A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/063214 external-priority patent/WO2021113577A1/en
Publication of JP2023503868A publication Critical patent/JP2023503868A/ja
Publication of JP2023503868A5 publication Critical patent/JP2023503868A5/ja
Pending legal-status Critical Current

Links

JP2022528714A 2019-12-05 2020-12-04 インターロイキン１５融合タンパク質およびプロドラッグ、ならびにそれらの組成物および方法 Pending JP2023503868A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944203P 2019-12-05 2019-12-05
US62/944,203 2019-12-05
PCT/US2020/063214 WO2021113577A1 (en) 2019-12-05 2020-12-04 Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof

Publications (2)

Publication Number Publication Date
JP2023503868A JP2023503868A (ja) 2023-02-01
JP2023503868A5 true JP2023503868A5 (https=) 2023-12-08

Family

ID=76222692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022528714A Pending JP2023503868A (ja) 2019-12-05 2020-12-04 インターロイキン１５融合タンパク質およびプロドラッグ、ならびにそれらの組成物および方法

Country Status (5)

Country Link
US (1) US20220402988A1 (https=)
EP (1) EP4069725A4 (https=)
JP (1) JP2023503868A (https=)
CN (1) CN115315434A (https=)
WO (1) WO2021113577A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021207669A1 (en) 2020-04-10 2021-10-14 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
JP2023540629A (ja) * 2020-09-16 2023-09-25 ベイジーン リミテッド インターロイキン１５構築物及び使用方法
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
BR112023018735A2 (pt) 2021-03-16 2023-11-28 Cytomx Therapeutics Inc Construtos de citocinas ativáveis mascarados e composições e métodos relacionados
US20230035308A1 (en) * 2021-07-02 2023-02-02 Aetio Biotherapy, Inc. Activatable monomeric cytokine-single chain (sc) fc fusion proteins and uses thereof
CA3238283A1 (en) * 2021-11-15 2023-05-19 Yangxin Fu Fusion protein construct taking interleukin 15 as active ingredient and use thereof
JP2025507733A (ja) * 2022-02-28 2025-03-21 ウーシー バイオロジクス アイルランド リミテッド Ｉｌ－１５変異体を含むヘテロ二量体ポリペプチド錯体とその使用
EP4695281A1 (en) * 2023-04-12 2026-02-18 CytomX Therapeutics, Inc. Masking polypeptides, activatable cytokine constructs, and related compositions and methods
CN120936384A (zh) * 2023-04-12 2025-11-11 西托姆克斯治疗公司 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法
WO2025113255A1 (zh) * 2023-11-28 2025-06-05 北京昌平实验室 抗肿瘤抗体与白介素15前体的双功能复合分子及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2011450C (en) * 1989-03-07 2002-06-04 Tadatsugu Taniguchi Recombinant b-chain of the il-2 receptor
MXPA02001417A (es) * 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
EP1777294A1 (en) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
EP2553101A4 (en) * 2010-04-02 2013-09-04 Univ Rochester PROTEASE-ACTIVATED CYTOKINES
US8507222B2 (en) * 2010-09-21 2013-08-13 Altor Bioscience Corporation Multimeric IL-15 soluble fusion molecules and methods of making and using same
EP3783098A1 (en) * 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
PT3444271T (pt) * 2013-08-08 2022-01-05 Inst Nat Sante Rech Med Modulocinas baseadas em il-15 e no domínio sushi de il-15ralfa
WO2019006472A1 (en) * 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
CN110437339B (zh) * 2018-05-04 2021-08-13 免疫靶向有限公司 一种以白介素15为活性成分的融合蛋白型药物前体
US20220002370A1 (en) * 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
CA3141626A1 (en) * 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2023503868A5 (https=)
JP2021522786A5 (https=)
US20210284716A1 (en) ACE2-Fc Trap
JP2023518518A5 (https=)
TWI759810B (zh) 信號調節蛋白α(signal-regulatory proteinα, SIRP-α)變體構築物及其用途
JP2023520922A5 (https=)
ES2203654T3 (es) Expresion citoplasmatica de anticuerpos, fragmentos de anticuerpos y moleculas de fusion de fragmentos de anticuerpos en e. coli.
US12187763B2 (en) Chromatography resin and uses thereof
JP3280376B2 (ja) 多価抗原結合性蛋白質
JP2016511279A5 (https=)
JP2025032113A5 (https=)
JP2021521822A5 (https=)
JP2002302500A (ja) 新規蛋白質及びこれを使用した薬剤の製法
JP2023518443A5 (https=)
WO1991019515A1 (en) Oligomeric immunoglobulin constant domain mutant with enhanced complement-mediated cytolytic activity
JP2016520053A5 (https=)
JP2005505293A5 (https=)
JP2022528053A5 (https=)
JP2025505434A (ja) タンパク質構造変化に基づくバイオ医薬プロドラッグプラットホーム
CN116173200A (zh) 一种TNF-α纳米抗体及其在制备溃疡性结肠炎药物中的应用
CN108300725B (zh) 可溶性单链抗体超抗原融合基因及蛋白和其制备与应用
JP2005518344A5 (https=)
JPH07173193A (ja) 生物学的活性ポリペプチド類
JPH05271291A (ja) 機能性ポリペプチド
JP4892717B2 (ja) ニワトリキメラ抗体およびその利用